WikiStock

Global Securities Firms Regulatory Inquiry App

English
Download
Home-News-

Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pr

iconBenzinga

2024-07-10 16:01

Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pr

  U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday.

  Shares of Kura Sushi USA, Inc. KRUS fell sharply in today's pre-market trading after the company posted downbeat results for its third quarter on Tuesday.

  Kura Sushi reported quarterly earnings of $0.00 per share which missed the analyst consensus estimate of $0.01. The company reported quarterly sales of $63.082 million which missed the analyst consensus estimate of $63.101 million, according to data from Benzinga Pro.

  Indivior shares fell 4.2% to $56.00 in the pre-market trading session.

  Here are some big stocks recording losses in today's pre-market trading session.

  • LegalZoom.com, Inc. LZ shares dipped 18.3% to $6.41 in pre-market trading after the company announced a CEO transition and lowered its full year guidance.
  • Stardust Power Inc. SDST declined 13.5% to $8.99 in pre-market trading after gaining around 9% on Tuesday.
  • 10x Genomics, Inc. TXG shares fell 9.8% to $16.46 in pre-market trading. On Tuesday, Goldman Sachs analyst Matthew Sykes maintained 10x Genomics with a Sell and lowered the price target from $26 to $16.
  • IDEAYA Biosciences, Inc. IDYA fell 6.4% to $36.13 in pre-market trading. IDEAYA priced $263 million public offering of 228,572 common shares and pre-funded warrants at $35 per share.
  • Hudson Pacific Properties, Inc. HPP shares declined 4.9% to $4.90 in pre-market trading.
  • uniQure N.V.QURE slipped 4.5% to $6.37 in pre-market trading. UniQure shares jumped 76% on Tuesday after the company announced updated interim data including up to 24 months of follow-up data from 29 treated patients enrolled in the ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntingtons disease.
  • Lufax Holding LtdLU shares fell 3.7% to $2.86 in pre-market trading after gaining 17% on Tuesday.
Disclaimer:The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.